MétaCan
Menu
Back to cohort
Record W4391116810 · doi:10.1093/cid/ciae010

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

2024· article· en· W4391116810 on OpenAlexaff
Michael G. Ison, Alberto Papi, Eugene Athan, Robert G. Feldman, Joanne M. Langley, Dong‐Gun Lee, Isabel Leroux‐Roels, Federico Martinón‐Torres, Tino F. Schwarz, Richard N. van Zyl-Smit, Céline Verheust, Nancy Dezutter, Olivier Gruselle, Laurence Fissette, Marie‐Pierre David, Lusiné Kostanyan, Veronica Hulstrøm, Aurélie Olivier, Marie Van der Wielen, Dominique Descamps, Mark N. Adams, Michael L. Adams, Clara Agutu, Elaine Jacqueline Akité, Ingrid Alt, Charles P. Andrews, Rafaelle Antonelli-Incalzi, Asmik Asatryan, Ghazaleh Bahrami, Elena Bargagli, Qasim Bhorat, Paul Bird, Przemysław Borowy, Céline Boutry, Carles Brotons Cuixart, David Browder, Judith C. Brown, Erik Buntinx, Donald P. Cameron, Laura Cámpora, Cyrille Cartier, Kenneth Chinsky, Melissa Choi, Eun Ju Choo, Delphine Collete, Maria Corral Carrillo, Susanna Cuadripani, Matthew Davis, Magali de Heusch, Ferdinandus de Looze, Marc De Meulemeester, Ferdinando De Negri, Nathalie De Schrevel, David DeAtkine, Viktoriya Dedkova, Peter Dzongowski, Tamara Eckermann, Brandon Essink, Karen Faulkner, Murdo Ferguson, Gregory N. Fuller, Isabel Maria Galan Melendez, Ivan Gentile, Wayne Ghesquière, Doria Grimard, Scott A. Halperin, Amardeep Heer, Laura Helman, Andre Hotermans, Tomáš Jelı́nek, Jackie Kamerbeek, Hyo Youl Kim, Murray Kimmel, Mark Koch, Satu Kokko, Susanna Koski, Shady Kotb, Antonio Lalueza, Jin Soo Lee, Muriel Lins, Johannes Lombaard, Akbar Mahomed, Mario Malerba, Céline Maréchal, Sandie Marion, Jean‐Benoît Martinot, Cristina Masuet‐Aumatell, Damien McNally, Carlos Eduardo Medina Pech, J M Gonzalez Galvan, Lise Mercati, Narcisa Mesaros, Dieter Mesotten, Essack Mitha, Kathryn Mngadi, Beate Moeckesch, Barnaby Montgomery, Linda Murray, Rhiannon Nally, Silvia Narejos Pérez, Joseph L. Newberg, Paul Nugent, Dolores Ochoa Mazarro, Harunori Oda, Maurizio Orso, Jacinto Ortiz Molina, Tatiana Pak, Dae Won Park, Meenakshi Patel, Minesh Patel, Anna Maria Pedro Pijoan, Alberto Borobia Perez, Lina Pérez–Breva, Mercè Pérez Vera, Claudia Pileggi, F. Pregliasco, Carol Pretswell, Dean Quinn, Michele D. Reynolds, В. В. Романенко, Jeffrey B. Rosen, Nathalie Roy, Belén Ruíz‐Antorán, Vardine Sahakyan, Hideaki Sakata, Joachim Sauter, Axel Schaefer, Izabela Sein Anand, José Antonio Serra Rexach, David Yang Shu, Andres Siig, William Simon, С. А. Смакотина, Katie Steenackers, Brigitte Stephan, Silvio Tafuri, Kenji Takazawa, Guy Tellier, Wim Terryn, Leslie Tharenos, Nicole Toursarkissian, Benita Ukkonen, Noah Vale, Pieter-Jan Van Landegem, Carline Vanden Abeele, Lode Vermeersch, Francesco Vitale, Olga Voloshyna, Judith M. White, Seong‐Heon Wie, Jonathan Wilson, Pedro Ylisastigui

Bibliographic record

VenueClinical Infectious Diseases · 2024
Typearticle
Languageen
FieldMedicine
TopicRespiratory viral infections research
Canadian institutionsNova Scotia Health AuthorityDalhousie University
FundersGlaxoSmithKline BiologicalsCilagGenentechShionogiBavarian NordicAmerican Thoracic SocietySouth African Thoracic SocietyGlenmark PharmaceuticalsBiogenNorthwestern UniversityPfizerModernaRegeneron PharmaceuticalsNational Institutes of HealthNovavaxAblynxCidara TherapeuticsAstraZenecaCSL BehringAlexion PharmaceuticalsWorld Health OrganizationSanofiGlaxoSmithKlineSeqirus
KeywordsMedicineVirologyRespiratory systemVirusPneumovirusParamyxoviridaeImmunologyViral diseaseInternal medicine

Abstract

fetched live from OpenAlex

BACKGROUND: The adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season. We evaluated efficacy and safety of 1 RSVPreF3 OA dose and of 2 RSVPreF3 OA doses given 1 year apart against RSV-LRTD over 2 RSV seasons post-dose 1. METHODS: In this phase 3, blinded trial, ≥60-year-olds were randomized (1:1) to receive RSVPreF3 OA or placebo pre-season 1. RSVPreF3 OA recipients were re-randomized (1:1) to receive a second RSVPreF3 OA dose (RSV_revaccination group) or placebo (RSV_1dose group) pre-season 2; participants who received placebo pre-season 1 received placebo pre-season 2 (placebo group). Efficacy of both vaccine regimens against RSV-LRTD was evaluated over 2 seasons combined (confirmatory secondary objective, success criterion: lower limits of 2-sided CIs around efficacy estimates >20%). RESULTS: The efficacy analysis comprised 24 967 participants (RSV_1dose: 6227; RSV_revaccination: 6242; placebo: 12 498). Median efficacy follow-up was 17.8 months. Efficacy over 2 seasons of 1 RSVPreF3 OA dose was 67.2% (97.5% CI: 48.2-80.0%) against RSV-LRTD and 78.8% (95% CI: 52.6-92.0%) against severe RSV-LRTD. Efficacy over 2 seasons of a first dose followed by revaccination was 67.1% (97.5% CI: 48.1-80.0%) against RSV-LRTD and 78.8% (95% CI: 52.5-92.0%) against severe RSV-LRTD. Reactogenicity/safety of the revaccination dose were similar to dose 1. CONCLUSIONS: One RSVPreF3 OA dose was efficacious against RSV-LRTD over 2 RSV seasons in ≥60-year-olds. Revaccination 1 year post-dose 1 was well tolerated but did not seem to provide additional efficacy benefit in the overall study population. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov: NCT04886596.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.082
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.405
Teacher spread0.370 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations162
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueClinical Infectious DiseasesSame topicRespiratory viral infections researchFrench-language works237,207